FDA’s PDUFA goal date is November 1, 2026; If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease; CAMBRIDGE, Mass., Ju ...
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — ...
Fallout 4's companions were much more fleshed out and reactive than the followers from previous entries in the series. They ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about metabolism, peptides, and the future of self-driven health ...
Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for chronic wounds, tissue repair, and degenerative disease, presented interim clinical data from the CAMPX Trial at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results